PRISM protocol: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in firstline treatment of patients with advanced or metastatic renal cell carcinoma

The combination of nivolumab, a programmed death-1 (PD-1) targeted monoclonal antibody, with the cytotoxic T-lymphocyte antigen-4 (CTLA-4) targeted antibody, ipilimumab, represents a new standard of care in the first-line setting for patients with intermediate- and poor-risk metastatic renal cell carcinoma (mRCC) based on recent phase III data.